---
title: "HENLIUS's patritumab deruxtecan has been granted FDA approval for the treatment of breast cancer"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/265871001.md"
description: "HENLIUS's patuzumab (POHERDY) has been approved by the U.S. FDA for the treatment of HER2-positive breast cancer. This is the seventh product of the company to be approved for sale overseas, with four of them approved in the United States"
datetime: "2025-11-14T08:33:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265871001.md)
  - [en](https://longbridge.com/en/news/265871001.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265871001.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/265871001.md) | [English](https://longbridge.com/en/news/265871001.md)


# HENLIUS's patritumab deruxtecan has been granted FDA approval for the treatment of breast cancer

HENLIUS (02696.HK) announced that it recently received an approval letter from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) of POHERDY (pertuzumab) 420mg/14mL (30mg/mL) injection, which is a trademark registered in the United States by N.V. Organon.

The approved indications are for use in combination with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not previously received anti-HER2 treatment or chemotherapy for metastatic disease; in combination with trastuzumab and chemotherapy as part of a comprehensive treatment regimen for adult patients with HER2-positive locally advanced, inflammatory, or early breast cancer as neoadjuvant therapy; and for adjuvant treatment in adult patients with HER2-positive early breast cancer at high risk of recurrence.

After the approval of POHERDY for market launch, the group has cumulatively obtained approvals for seven products overseas, four of which have been approved for marketing in the United States

### 相關股票

- [HENLIUS (02696.HK)](https://longbridge.com/zh-HK/quote/02696.HK.md)

## 相關資訊與研究

- [Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe](https://longbridge.com/zh-HK/news/280997570.md)
- [ECB MAKHLUF URGES CAUTION AMIDST REAL UNCERTAINTY.](https://longbridge.com/zh-HK/news/281346843.md)
- [H-1B visa wages: Is US comparing foreign workers with Americans unfairly?](https://longbridge.com/zh-HK/news/281008314.md)
- [Ubtech Robotics Corp posts FY net loss attributable RMB703.2 mln](https://longbridge.com/zh-HK/news/281211181.md)
- [Ganfeng Lithium Turns to 2025 Profit](https://longbridge.com/zh-HK/news/281121946.md)